查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1591951

高血壓藥物市場：依治療方法、分析、類型、分佈分類 - 全球預測 2025-2030

Hypertension Drug Market by Therapy (Alpha Blockers, Angiotensin Converting Enzyme Inhibitor, Angiotensin Receptor Blockers), Analysis (Pulmonary Hypertension Drugs, Systemic Hypertension Drugs), Type, Distribution - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年高血壓藥物市值為268.8億美元，預計2024年將達292億美元，複合年成長率為8.73%，到2030年將達到483.2億美元。

高血壓藥物對於控制高血壓至關重要，由於與生活方式相關的健康問題越來越多，高血壓已成為世界各地的流行病。高血壓藥物包括多種抗高血壓藥物，如利尿劑、 BETA阻斷劑、ACE抑制劑和鈣通道阻斷劑，旨在降低血壓並降低心臟病和中風的風險。由於高血壓盛行率不斷上升、人口老化以及心血管健康意識不斷增強，這個市場變得勢在必行。其應用涵蓋預防性和治療性治療，最終用於醫院、診所和居家醫療的持續管理。影響該市場的主要成長要素包括對有效和更安全的藥物治療的需求激增、藥物傳遞技術的進步以及個人化醫療研究投資的增加。開發組合藥物以提高療效和探索數位健康解決方案（例如遠端監控）以提高患者的依從性和結果有顯著的機會。然而，市場成長受到嚴格的監管要求、現有藥物的潛在副作用以及開發新藥的高成本的限制。新穎的、具成本效益的治療策略可以解決這些挑戰。創新領域包括利用人工智慧進行藥物發現、利用基因組學進行個人化高血壓治療以及增強藥物配方技術。公司應該關注醫療保健基礎設施到位並且正在進行意識提升宣傳活動的新興市場。高血壓藥物市場受到高度監管和競爭，需要不斷適應技術進步和人口變化。因此，為了在這個動態的市場環境中取得成功，公司應該投資策略聯盟和夥伴關係，並專注於全面的患者解決方案，同時平衡成本、有效性和可及性。

主要市場統計
基準年[2023] 268.8億美元
預測年份 [2024] 292億美元
預測年份 [2030] 483.2億美元
複合年成長率（%） 8.73%

市場動態：揭示快速發展的高血壓藥物市場的關鍵市場洞察

供需的動態交互作用正在改變高血壓藥物市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 提高對高血壓相關併發症的認知
    • 隨著人口老化，高血壓盛行率增加
    • 高血壓藥物治療進展
  • 市場限制因素
    • 偏遠地區高血壓藥物缺乏
  • 市場機會
    • 私人和政府機構不斷增加的研發舉措
    • 開發新藥日益受到關注
  • 市場挑戰
    • 人們越來越擔心治療方法的副作用
    • 替代學名藥的增加

波特的五力戰略工具駕馭高血壓藥物市場

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解高血壓藥物市場的外部影響

外部宏觀環境因素在塑造高血壓藥物市場的表現動態中起著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助企業預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解高血壓治療藥物市場的競爭狀況

對高血壓藥物市場的詳細市場佔有率分析可以對供應商的業績進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 高血壓藥物市場定位矩陣供應商績效評估

FPNV 定位矩陣是評估高血壓藥物市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，描繪高血壓藥物市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，高血壓藥物市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 提高對高血壓相關併發症的認知
      • 高血壓盛行率增加和人口老化
      • 高血壓藥物治療進展
    • 抑制因素
      • 偏遠地區買不到高血壓藥
    • 機會
      • 擴大私人和政府的研發力道
      • 開發新藥日益受到關注
    • 任務
      • 人們越來越擔心治療方案的副作用
      • 學名藥替代品增加
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章 高血壓藥物市場治療

  • α阻斷劑
  • 血管張力素轉化酵素抑制劑
  • 血管收縮素受體阻斷劑
  • BETA阻斷劑血管擴張劑
  • 鈣離子通道阻斷劑
  • 利尿劑
  • 腎素抑制劑

第7章高血壓治療藥物市場分析（市場分析）

  • 肺動脈高壓治療藥
  • 全身性高血壓治療藥

第8章高血壓藥物市場：依類型

  • 聯合治療
  • 單一療法

第9章 高血壓藥物市場經銷商

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第10章北美與南美高血壓藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太地區高血壓藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲的高血壓藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Daiichi Sankyo Company, Limited
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Lupin Limited
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Limited
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-43127F727999

The Hypertension Drug Market was valued at USD 26.88 billion in 2023, expected to reach USD 29.20 billion in 2024, and is projected to grow at a CAGR of 8.73%, to USD 48.32 billion by 2030.

Hypertension drugs are crucial in managing high blood pressure, a condition prevalent globally due to increasing lifestyle-induced health issues. The scope of these drugs includes a range of antihypertensives, such as diuretics, beta-blockers, ACE inhibitors, and calcium channel blockers, designed to lower blood pressure and reduce the risk of heart diseases and strokes. This market is essential due to the growing prevalence of hypertension, the aging population, and rising awareness about cardiovascular health. Its applications extend across both preventive and therapeutic treatments, with end-use in hospitals, clinics, and home-based care for continuous management. Key growth factors influencing this market include the surge in demand for effective and safer drug regimens, technological advancements in drug delivery, and increased investment in research for personalized medicine. Notable opportunities exist in the development of combination drugs, which offer enhanced efficacy, and in exploring digital health solutions like remote monitoring to improve patient compliance and outcomes. However, market growth encounters limitations such as stringent regulatory requirements, potential side effects of existing medications, and the high cost of novel drug development. Cost-effective and novel therapeutic strategies could address these challenges. Innovation areas include exploiting artificial intelligence for drug discovery, leveraging genomics for personalized hypertensive medications, and enhancing drug formulation technologies. Businesses should focus on emerging markets with increasing healthcare infrastructure and awareness campaigns. The hypertension drug market, characterized by its regulated and competitive nature, requires ongoing adaptation to technological advancements and demographic shifts. Therefore, companies should invest in strategic collaborations and partnerships that focus on comprehensive patient solutions, balancing cost, efficacy, and accessibility to thrive in this dynamic market environment.

KEY MARKET STATISTICS
Base Year [2023] USD 26.88 billion
Estimated Year [2024] USD 29.20 billion
Forecast Year [2030] USD 48.32 billion
CAGR (%) 8.73%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Hypertension Drug Market

The Hypertension Drug Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rise in awareness related to complications associated with hypertension
    • Increasing prevalence of hypertension coupled with geriatric population
    • Advances in pharmacologic treatment of hypertension
  • Market Restraints
    • Unavailability of hypertension drugs in remote areas
  • Market Opportunities
    • Growing initiatives by private and government organizations for R&D
    • Increasing focus on development of new drugs
  • Market Challenges
    • Increased concern of side-effects of treatment options
    • Rising number of alternate generic drugs

Porter's Five Forces: A Strategic Tool for Navigating the Hypertension Drug Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Hypertension Drug Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Hypertension Drug Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Hypertension Drug Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Hypertension Drug Market

A detailed market share analysis in the Hypertension Drug Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Hypertension Drug Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Hypertension Drug Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Hypertension Drug Market

A strategic analysis of the Hypertension Drug Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Hypertension Drug Market, highlighting leading vendors and their innovative profiles. These include AstraZeneca PLC, Bayer AG, Boehringer Ingelheim International GmbH, Daiichi Sankyo Company, Limited, F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Lupin Limited, Merck KGaA, Novartis AG, Pfizer Inc., Sanofi S.A., Sun Pharmaceutical Industries Limited, and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Hypertension Drug Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Therapy, market is studied across Alpha Blockers, Angiotensin Converting Enzyme Inhibitor, Angiotensin Receptor Blockers, Beta Blockers Vasodilators, Calcium Channel Blockers, Diuretics, and Renin Inhibitors.
  • Based on Analysis, market is studied across Pulmonary Hypertension Drugs and Systemic Hypertension Drugs.
  • Based on Type, market is studied across Combination Therapy and Mono Therapy.
  • Based on Distribution, market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rise in awareness related to complications associated with hypertension
      • 5.1.1.2. Increasing prevalence of hypertension coupled with geriatric population
      • 5.1.1.3. Advances in pharmacologic treatment of hypertension
    • 5.1.2. Restraints
      • 5.1.2.1. Unavailability of hypertension drugs in remote areas
    • 5.1.3. Opportunities
      • 5.1.3.1. Growing initiatives by private and government organizations for R&D
      • 5.1.3.2. Increasing focus on development of new drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Increased concern of side-effects of treatment options
      • 5.1.4.2. Rising number of alternate generic drugs
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Hypertension Drug Market, by Therapy

  • 6.1. Introduction
  • 6.2. Alpha Blockers
  • 6.3. Angiotensin Converting Enzyme Inhibitor
  • 6.4. Angiotensin Receptor Blockers
  • 6.5. Beta Blockers Vasodilators
  • 6.6. Calcium Channel Blockers
  • 6.7. Diuretics
  • 6.8. Renin Inhibitors

7. Hypertension Drug Market, by Analysis

  • 7.1. Introduction
  • 7.2. Pulmonary Hypertension Drugs
  • 7.3. Systemic Hypertension Drugs

8. Hypertension Drug Market, by Type

  • 8.1. Introduction
  • 8.2. Combination Therapy
  • 8.3. Mono Therapy

9. Hypertension Drug Market, by Distribution

  • 9.1. Introduction
  • 9.2. Hospital Pharmacy
  • 9.3. Online Pharmacy
  • 9.4. Retail Pharmacy

10. Americas Hypertension Drug Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Hypertension Drug Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Hypertension Drug Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AstraZeneca PLC
  • 2. Bayer AG
  • 3. Boehringer Ingelheim International GmbH
  • 4. Daiichi Sankyo Company, Limited
  • 5. F. Hoffmann-La Roche Ltd.
  • 6. Gilead Sciences, Inc.
  • 7. GlaxoSmithKline PLC
  • 8. Johnson & Johnson Services, Inc.
  • 9. Lupin Limited
  • 10. Merck KGaA
  • 11. Novartis AG
  • 12. Pfizer Inc.
  • 13. Sanofi S.A.
  • 14. Sun Pharmaceutical Industries Limited
  • 15. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. HYPERTENSION DRUG MARKET RESEARCH PROCESS
  • FIGURE 2. HYPERTENSION DRUG MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL HYPERTENSION DRUG MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS HYPERTENSION DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS HYPERTENSION DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES HYPERTENSION DRUG MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES HYPERTENSION DRUG MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC HYPERTENSION DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC HYPERTENSION DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA HYPERTENSION DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA HYPERTENSION DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. HYPERTENSION DRUG MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. HYPERTENSION DRUG MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. HYPERTENSION DRUG MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL HYPERTENSION DRUG MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. HYPERTENSION DRUG MARKET DYNAMICS
  • TABLE 7. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY ALPHA BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY ANGIOTENSIN CONVERTING ENZYME INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY ANGIOTENSIN RECEPTOR BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY BETA BLOCKERS VASODILATORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY DIURETICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY RENIN INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY PULMONARY HYPERTENSION DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY SYSTEMIC HYPERTENSION DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY MONO THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS HYPERTENSION DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES HYPERTENSION DRUG MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC HYPERTENSION DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA HYPERTENSION DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 193. HYPERTENSION DRUG MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 194. HYPERTENSION DRUG MARKET, FPNV POSITIONING MATRIX, 2023